Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

FET fusion oncoproteins enrich SWI/SNF complex subtypes and interaction partners

ABSTRACT: • Abstract: FET fusion oncoproteins, containing the N-terminal of a FET protein (FUS, EWSR1 and TAF15) together with a DNA-binding transcription factor partner, are characteristic for around 20 different sarcomas and leukemias, including myxoid liposarcoma (MLS) and Ewing sarcoma (EWS). FET oncoproteins interact with all three main subtypes of the SWI/SNF chromatin remodeling complexes cBAF, PBAF and GBAF, resulting in epigenetic changes and oncogenic gene expression patterns. We developed a comprehensive immunoprecipitation (IP) protocol followed by quantitative mass spectrometry (QMS) analysis using a global approach for relative quantification with chemical tandem mass tag (TMT) labels. We employed two immunoprecipitation strategies, by pulling down either all SWI/SNF complexes using BRG1 as a target or FET-FOP-bound SWI/SNF complexes using the fusion oncoproteins FUS-DDIT3 or EWSR1-FLI1 as a target. This approach allowed us to assess differences between SWI/SNF composition and interaction partners in MLS and EWS cells, as well as determine the composition and interactome of FET-FOP-bound SWI/SNF complexes.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

DISEASE(S): Acute Leukemia

SUBMITTER: Johannes Fuchs

LAB HEAD: Anders Ståhlberg

PROVIDER: PXD047503 | Pride | 2025-09-22

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	4231_ProteinPSM_PullDown_NoNorm_1mc_SPS55_Lumos_210702_13to22.xlsx	Xlsx
	4231_ProteinPeptide_PullDown_NoNorm_1mc_SPS55_Lumos_210702_13to22.xlsx	Xlsx
	4231_PullDown_Abundences_NoNorm_1mc_SPS55_Lumos_210702_13to22.xlsx	Xlsx
	4231_PullDown_NoNorm_1mc_SPS55_Lumos_210702_13to22.msf	Msf
	4231_PullDown_NoNorm_1mc_SPS55_Lumos_210702_13to22.pdResult	Other

Items per page:

1 - 5 of 15

Similar Datasets

Identification of FET-oncoprotein-interacting proteins by immunoprecipitation and mass spectrometry analysis in sarcoma cell lines

Project description:The FET family of fusion oncogenes carry one of the three genes, FUS, EWSR1 or TAF15, as 5’‑partners juxtaposed to one of many different DNA binding transcription factor genes as 3’‑partners. FET fusion oncogenes are pathognomonic for many types of sarcoma and leukemia, such as FUS-DDIT3 in myxoid liposarcoma (MLS) and EWSR1-FLI1 in Ewing sarcoma (EWS). We used recombinant FET N-terminal domains in a pulldown screen to find interaction partners to the FET proteins and identified components of the SWI/SNF complex. The ~2 MDa SWI/SNF chromatin remodeling complex utilizes energy from ATP hydrolysis to remodel nucleosomes and expose DNA. We used immunoprecipitation followed by mass spectrometry or western blot analysis to extensively characterize the interaction between FET fusion oncoproteins and the SWI/SNF complex.

2019-03-13 | PXD012680 | Pride

Differences in gene expression between myxoid liposarcoma and Ewing sarcoma cell lines

Project description:FET fusion oncoproteins, containing the N-terminal of a FET protein (FUS, EWSR1 and TAF15) together with a DNA-binding transcription factor partner, are characteristic for around 20 different sarcomas and leukemias, including myxoid liposarcoma (MLS) and Ewing sarcoma (EWS). Many of these tumors have few other genetic abberrations. Using RNA-sequencing on MLS and EWS cell lines, we showed that gene expression patterns varied between FET sarcoma subtypes. Together with other data, the information from this experiment can help to determine the oncogenic mechanism in FET sarcomas and how a common oncogenic mechanism can give rise to different tumor types, explaining the tumor-type specificity of FET oncoproteins.

2025-09-22 | GSE248354 | GEO

Differential chromatin landscape in myxoid liposarcoma and Ewing sarcoma

Project description:A subgroup of sarcomas and leukemias is defined by characteristic FET (FUS, EWSR1, TAF15) fusion oncogenes. Myxoid liposarcoma (MLS) and Ewing sarcoma (EWS) are the most common entities characterized by the fusion oncogenes FUS-DDIT3 and EWSR1-FLI1, respectively. Here, we performed ATAC-Seq on the cell lines MLS 1765-92 and EWS TC-71 to characterize and compare their chromatin landscape.

2025-09-22 | GSE235218 | GEO

EWS and FUS Bind a Subset of Transcribed Genes Encoding Proteins Enriched in RNA Regulatory Functions

Project description:Background FUS (TLS) and EWS (EWSR1) belong to the FET-protein family of RNA and DNA binding proteins. FUS and EWS are structurally and functionally related and participate in transcriptional regulation and RNA splicing. FUS and EWS are identified in translocation generated cancer fusion proteins and involved in the human neurological diseases amyotrophic lateral sclerosis and fronto-temporal lobar degeneration. Results To determine the gene regulatory functions of FUS and EWS at the level of chromatin, we have performed Chromatin Immunoprecipitation followed by Next Generation Sequencing (ChIP-Seq). Our results show that FUS and EWS bind to a subset of actively transcribed genes, that binding often is in the 3’ end of genes, and that binding overlaps with RNA polymerase II. Functional examinations of selected target genes verified that FUS and EWS can regulation expression. Gene Ontology (GO) analyses showed that FUS and EWS target genes preferentially encode proteins involved in regulatory processes at the RNA level. Conclusions The presented results yield new insights into gene interactions of EWS and FUS and have identified a set of FUS and EWS target genes involved in pathways at the RNA regulatory level with potential to mediate normal and disease-associated functions of the FUS and EWS proteins.

2015-11-19 | GSE73492 | GEO

FET fusion oncoprotein-regulated genes in HT1080 cell line

Project description:Some specific sarcomas and leukemias are defined by characteristic FET (FUS, EWSR1, TAF15) fusion oncogenes. Myxoid liposarcoma and Ewing sarcoma are the most common entities characterized by FUS-DDIT3 and EWSR1-FLI1, respectively. Here, we performed whole transcriptome analysis of HT1080 cells with either ectopic FUS-DDIT3 or ectopic EWSR1-FLI1 expression.

2019-03-12 | GSE125941 | GEO

Correlation between gene expression responses to FUS, EWS, and TAF15 reduction and the stress granule sequestering capacity

Project description:Analysis of differentially expressed genes after siRNA mediated knock-down of the FET-family of proteins; the FUS, EWS, and TAF15 proteins. The FET-proteins are thought to function as transcription factors, and this hypothesis is tested in the present study. Results provide important information of the genes which expression are controlled by the FET-family of proteins. Total RNA obtained HEK293-cells transfected with siRNA targeted against the FUS, EWS, or TAF15 mRNA, or a combination of all three of them. Control cells are transfected with an equal amount of unspecific siRNA without known targets.

2012-02-07 | E-GEOD-35578 | biostudies-arrayexpress

Genes regulated by JAK1/2 inhibitor ruxolitinib and myxoid liposarcoma-specific fusion onccogene FUS-DDIT3 in HT1080 cells.

Project description:Sarcomas and leukemias that are characterized by FET (FUS, EWSR1, TAF15) fusion oncogenes consist of more than 20 entities. Myxoid liposarcoma, one of the most common FET sarcoma types, is defined by the FUS-DDIT3 or the less common EWSR1-DDIT3 fusion oncogene. Previously, JAK-STAT signaling have been connected to cancer stem cell properties and chemotherapy resistance in myxoid liposarcoma, but the role of FUS-DDIT3 is not known. Therefore, we treated HT1080 fibrosarcoma cells expression FUS-DDIT3 with JAK1/2 inhibitor ruxolitinib and performed RNA sequencing of treated and control cells. Additionally, we analyzed native HT1080 cells to be able to compare the induced gene expression changes due to FUS-DDIT3 expression with those induced by JAK-STAT pathway inhibition.

2022-01-14 | GSE149650 | GEO

The FUS-DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma

Project description:Mammalian SWI/SNF (mSWI/SNF or BAF) ATP-dependent chromatin remodeling complexes play critical roles in governing genomic architecture and gene expression and are frequently perturbed in human cancers. Transcription factors (TFs), including fusion oncoproteins, can bind to BAF complex surfaces to direct chromatin targeting and accessibility, often activating oncogenic gene loci. Here, we demonstrate that the FUS-DDIT3 fusion oncoprotein hallmark to myxoid liposarcoma (MLPS) inhibits BAF complex-mediated remodeling of adipogenic enhancer sites via sequestration of the adipogenic TF, CEBPB, from the genome. In mesenchymal stem cells, small molecule inhibition of BAF complex ATPase activity attenuates adipogenesis via failure of BAF-mediated DNA accessibility and gene activation at CEBPB target sites genome-wide. BAF chromatin targeting and gene expression profiles of FUS-DDIT3-expressing cell lines and primary tumors exhibit similarity to SMARCB1-deficient BAF loss-of-function tumor types. These data present a novel mechanism by which fusion oncoproteins generate BAF complex loss-of-function phenotypes, independent of deleterious subunit mutations.

2022-04-18 | GSE179720 | GEO

Correlation between gene expression responses to FUS, EWS, and TAF15 reduction and the stress granule sequestering capacity

2012-02-07 | GSE35578 | GEO

Cancer-specific retargeting of BAF complexes by a prion-like domain [RNA-Seq]

Project description:Alterations in the function of transcriptional regulators can orchestrate oncogenic programs that are critical for the transformation and survival of cancer cells. Here we show that the BAF chromatin remodeling complex, which is mutated in over 20% of human tumors, interacts with EWSR1, a member of the FET family of proteins containing prion-like domains that are frequent partners in oncogenic fusions with transcription factors. In Ewing sarcoma, characterized by the EWS-FLI1 fusion, we find that the BAF complex is recruited by EWS-FLI1 to tumor specific enhancers at GGAA microsatellite repeats and contributes to the activation of target genes. This process depends on tyrosine residues that are necessary for the aggregation properties of the EWSR1 prion-like domain and is a neomorphic feature of EWS-FLI1 compared to the wild type ETS transcription factor FLI1. Furthermore, fusion of short fragments of the EWSR1 prion-like domain to FLI1 is sufficient to recapitulate EWS-FLI1-mediated gene expression. Our studies demonstrate that the aggregation properties of prion-like domains can retarget chromatin regulatory complexes to establish and maintain oncogenic gene expression and proliferation.

2017-08-24 | GSE94277 | GEO